Abstract library

1630 results for "Gastrointestinal Stromal Tumors (GISTs)".
#349 Gastrointestinal Stromal Tumor (GIST) Of The Esophagus In A Patient With MEN-1 And-Related Pancreatic Gastrinoma
Introduction: Both Multiple Endocrine Neoplasia type 1 (MEN-1; OMIM #613733)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs; OMIM #606764) are rare neoplasms and their association has been rarely reported so far.
Conference:
Category: Basic
Presenting Author: Dr Roberta E Rossi
#426 An Esophageal Gastrointestinal Stromal Tumor (GIST) in a Patient with MEN-1 Related Pancreatic Gastrinoma
Introduction: Both multiple endocrine neoplasia type 1 (MEN1)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs) are rare neoplasms, and their association has been rarely reported.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Roberta E Rossi
#985 Periampulary and Pancreatic Neuroendocrine Neoplasms with Duodenal Stromal Gastrointestinal Tumors in Patients with Type 1 Neurofibromatosis: Two Case Reports
Introduction: We describe two cases of neuroendocrine tumors (NETs) in patients with neurofibromatosis type 1 (NF1) associated with gastrointestinal stromal tumors (GISTs).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Cristina Ridolfi
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#279 Coexistence of a Somatostatin-Producing Carcinoma of Duodenum and a Jejuna Gastrointestinal Stromal Tumor (GIST) in a Patient with Von Recklinghausen’s Disease
Introduction: Duodenal neuroendocrine tumors comprise 2-3% of all neuroendocrine tumors of the gastrointestinal tract. Coexistence of NF-1, NET and GIST is rare and only five cases have been described in the literature.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Vasiliki Daraki
#2911 Pancreatic Neuroendocrine Neoplasms and GastroIntestinal Stromal Tumours: A Single-Institution Experience of a Rare Association and Review of the Literature
Introduction: Pancreatic neuroendocrine neoplasms (pNENs) and gastrointestinal stromal tumours (GISTs) are both rare neoplasms, and they have an estimated incidence of about 1/100,000 per year and about 1-1.5/100,000 per year, respectively.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#260 Risk of Hepatic and Gastrointestinal (GI) Events in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
Introduction: NET derives from peptide- and hormone-producing cells scattered throughout the body. In excess, these can lead to many clinical manifestations, including GI events (ex. enteritis, and liver disease).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Chi-Chang Chen
Authors: Hess G P, Liu Z M, Chen C C, Yao J C, ...
#1841 The Characteristics and Survivals of Gastrointestinal Neuroendocrine Tumors, A Single Center Experience from Developing Country
Introduction: Gastrointestinal neuroendocrine tumors (GINETs) are a heterogeneous group of tumors with variable behaviors. We analyzed baseline characteristics and outcomes of GINETs and impact of the tumor grade on the overall survival.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Doctor Jamshed Ali
Authors: Ali J, Qubtia M, Hassan A U, Ahmad U, ...
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#1851 Ecological Study to Assess the Management of Gastroenteropancreatic Neuroendocrine Tumors in Spain
Introduction: Neuroendocrine tumors (NET) have widely varying characteristics, localizations, and treatments. Consequently, a multidisciplinary approach to diagnosis and treatment is necessary. Given the heterogeneous management of this disease, we conducted an ecological survey to assess usual clinical practice in Spain.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Raquel Guardeño